ClinVar Miner

Submissions for variant NM_000169.2(GLA):c.1021G>A (p.Glu341Lys) (rs869312214)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Integrated Genetics/Laboratory Corporation of America RCV000781425 SCV000919443 pathogenic Fabry disease 2018-08-21 criteria provided, single submitter clinical testing Variant summary: GLA c.1021G>A (p.Glu341Lys) results in a conservative amino acid change located in the Alpha galactosidase A, C-terminal beta-sandwich domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. Other variants at this codon have been reported in the litertature in association with Fabry Disease (E341G, E341D). The variant was absent in 178226 control chromosomes. c.1021G>A has been reported in the literature in multiple individuals affected with Fabry Disease, inlcuding a large family with segregation data (Beyer_1999). These data indicate that the variant is very likely to be associated with disease. In vitro alpha-Gal activity was reported as 0% of WT (Lukas_2013). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.